Company intelligence / Profile preview

P!NK

Ness Ziona, Israel

Ownership: Private
Development stage: Other

Overview

PiNK Biopharma was an Israeli biotechnology company focused on developing novel immune checkpoint inhibitors to enhance the activity of Natural Killer (NK) cells against cancer. The company's lead program was a monoclonal antibody (mAb14) designed to target cell surface Proliferating Cell Nuclear Antigen (csPCNA), which acts as an inhibitory ligand for the NK cell receptor NKp44. By blocking this interaction, the therapy aimed to reactivate NK cell cytotoxicity against malignant cells in indications such as Acute Myeloid Leukemia (AML) and Cutaneous T-cell Lymphoma (CTCL). The company was a graduate of the FutuRx incubator and operated in Ness Ziona, Israel, before its dissolution in 2025.

Therapeutic areas: Oncology
Modalities: Monoclonal antibodyBiologic
Industry: Biotech

Partnerships

FutuRxJohnson & Johnson InnovationTakeda VenturesOrbiMed

Beyond the preview

Go deeper on P!NK.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on P!NK.

Explore the full profile